Reducing the burden of malaria in disease-endemic countries, by DISCOVERING, DEVELOPING & DELIVERING new, effective and affordable antimalarial drugs.
The 10/90 gap: A fatal imbalance

Global health research spend

Global disease burden

10%

90%
Product Development Partnerships forged to correct the imbalance

With the support of donors, PDPs bring together academic and pharmaceutical partners to make neglected disease research bear fruit.
Product Development Partnerships
Operating Model

Syndicated investment
Governments, philanthropic

Partnership Funders, industry, academia, National Governments, UN agencies, CROs

Virtual development organisation R&D and portfolio management

Independent expert scientific review Supports clinical candidate selection and stage-gating

Strong contractual framework Increases access and good governance
Three-way leverage of donor funds

- PDP FUNDERS
- PARTNER IN-KIND
- NEGOTIATED SERVICE CONTRACTS
- IN-COUNTRY PARTNERS

The diagram illustrates the three-way leverage of donor funds through partnerships.
Collaborations result in high impact affordable products

23 products launched from Swiss PDPs out of 42 from all PDPs
Address Immediate Patient Needs & Deliver Innovative Products: Short- and Long-term Objectives

New chemical entities (NCEs)
New formulations
New indications for existing drugs
Completing registration dossier
Geographical extension

Long-term projects
Medium-term projects
Short-term projects

Research
Translation
Development
Implementation

> 5 years
3-5 years
1-2 years
Forging an integrated global effort

- Pharmaceuticals companies: 28 | 31 | xx
- Biotech companies: 13 | 30 | xx
- Universities: 56 | 64 | xx
- Research institutes: 38 | 66 | xx
- Clinical sites: 72 | 57 | 32
- Government agencies: 50 | 19 | 35

MMV | DNDi | FIND
Value through health impact

Saving lives

Coartem® Dispersible

- 300 000 000 * treatment courses delivered
- 60 000 000 to 87 000 000** children cured
- 340 000* children’s lives saved

Injectable artesunate

- 36 300 000 vials delivered since WHO pre-qualification
- 55%*** reduction in mortality vs quinine in DRC
- 200 000 - 240 000**** children’s lives saved

---

* Novartis communication December 2015
** estimates based upon drug distribution data, epidemiology / testing data and clinical efficacy data (PCR-corrected 28-day cure rate for Coartem® dispersible) and observational data
**** estimates based upon drug distribution data and clinical efficacy data
Advantages of PDPs

- ACCELERATING APPROVAL IN DISEASE ENDEMIC COUNTRIES
- INVESTING IN POST-APPROVAL SAFETY REGISTRIES
- MAINTAINING LONG TERM FINANCIAL STABILITY
- BUILDING CAPACITY IN DISEASE ENDEMIC COUNTRIES
MMV

is grateful for the financial support from the following organizations

Australian Aid
Bill & Melinda Gates Foundation
ExxonMobil
GHIT Fund
Irish Aid
National Institutes of Health
Newcrest Mining Limited
Norad
Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra
UK aid from the British people
UNITAID
USAID
Wellcome Trust
World Health Organization
THANK YOU!